The global hemodialysis vascular grafts market size was valued at USD 209.1 million in 2018. It is likely to expand at a CAGR of 4.1 % over the forecast period. Increasing prevalence of renal disorders, growing adoption of biological access grafts, and technological advancements in these products are some of the factors expected to drive the market over the forecast period.
Limited availability of kidney donors is leading to an increase in the number of patients with chronic kidney disease (CKD) opting for hemodialysis. As a result, the demand for hemodialysis vascular grafts is projected to witness an upswing during the forecast period.
Developing economies have large unmet population suffering from CKD, due to delayed diagnosis, comparatively poor healthcare facilities, unavailability of suitable kidney donors, and presence of cost-sensitive patient pool. Hence, kidney transplantation procedure has less preference as compared to hemodialysis procedure in developing economies, owing to presence of cheaper alternatives such as vascular access grafts.
Increasing awareness about CKD in these countries is anticipated to boost the growth of the market over the forecast period. For instance, India Renal Foundation is a non-governmental organization involved in conducting awareness programs for prevention of kidney diseases and have conducted about 15,000 programs till date.
Patients undergoing dialysis must get long-term central venous catheterization, while they also have alternate option of arteriovenous graft (AVG). This AVG is used in case, where all superficial veins of patients are exhausted due to continuous process of hemodialysis. Although synthetic polytetrafluoroethylene (PTFE) grafts are becoming popular worldwide, they have several disadvantages such as steal syndrome, high risk of infection, and long patency. As compared to synthetic, biological access grafts have higher patient benefits such as lower risk of infection and fewer chances of rejections.
On the basis of raw material, the market has been segmented into polyester, polytetrafluoroethylene, polyurethane, and biological materials. The polytetrafluoroethylene segment dominated the market and accounted for 45.0% of the overall revenue in 2018. The growth of the segment can be attributed to factors such as better adhesion and pliability as compared to other materials and similar patency as compared to other synthetic products.
Hemodialysis access products manufactured using single component polyester-polyurethane are hydrolytically unstable after implantation. C. R. Bard, Inc. developed Vectra for vascular access, which is composed of polyetherurethaneurea and siloxane that contains surface-modifying additive. This product shows rapid hemostasis, within 1 to 5 minutes of needle withdrawal. Launch of novel products is expected to contribute to the growth of the overall hemodialysis vascular grafts market.
Biological vascular access grafts are made by human saphenous veins and other tissue engineered materials. These grafts are preferred as compared to synthetic types due to less number of infections, higher patency, and higher durability as compared to other synthetic grafts. These grafts are ideal solutions that can be used for treating vascular graft infections and for patients who are at risk of AV access infections. The segment is likely to witness a CAGR of 3.3% during the forecast period.
North America accounted for the highest revenue share in 2017 in the global arena. Higher healthcare expenditure as a percentage of GDP, higher preference for biological and tissue engineered vascular access grafts, and increased number of patients with CKD are among the primary growth stimulants for the regional market.
U.S. alone accounted for over 27.0% of the global market revenue in 2018. Higher number of CKD patients and growing penetration of synthetic hemodialysis vascular access grafts are supplementing the growth of the market. Europe represented approximately 24.0% of the total revenue in 2017, due to increased preference for hemodialysis as compared to peritoneal dialysis. Growing acceptance of these products for hemodialysis in this region is augmenting the regional market.
The Asia Pacific market is poised to witness the highest CAGR of 6.6% between 2018 and 2025, due to mounting cases of patients suffering from CKD, unavailability of suitable kidney donors, and increasing per capita healthcare expenditure. Rising number of dialysis procedures in the region is projected to create lucrative growth opportunities for the market in Asia Pacific over the forecast period.
The market is oligopolistic and dominated by few companies such as W.L. Gore & Associates; C. R. Bard, Inc.; Terumo Medical Corporation; LeMaitre Vascular, Inc.; and Getinge AB. Other companies operating in the market are Vascular Genesis; InnAVasc Medical, Inc.; CryoLife, Inc.; Merit Medical Systems, Inc.; and Proteon Therapeutics, Inc. The competition in the market is anticipated to increase over the forecast period due to launch of new and technologically advanced cost-effective grafts.
Report Attribute |
Details |
Market size value in 2020 |
USD 227.03 million |
Revenue forecast in 2025 |
USD 276.5 million |
Growth Rate |
CAGR of 4.1% from 2018 to 2025 |
Base year for estimation |
2017 |
Historical data |
2014 - 2016 |
Forecast period |
2018 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2018 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, trends |
Segments covered |
Raw material type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East; Africa |
Country scope |
U.S.; Canada; U.K.; Germany; China; Japan; Brazil; Mexico; South Africa |
Key companies profiled |
W.L. Gore & Associates; C. R. Bard, Inc.; Terumo Medical Corporation; LeMaitre Vascular, Inc.; Getinge AB; Vascular Genesis; InnAVasc Medical, Inc.; CryoLife, Inc.; Merit Medical Systems, Inc.; and Proteon Therapeutics, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global hemodialysis vascular grafts market report on the basis of raw material type and region:
Raw Material Outlook (Revenue, USD Million, 2014 - 2025)
Polyester
Polytetrafluoroethylene
Polyurethane
Biological Materials
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S.
Canada
Europe
U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
b. The global hemodialysis vascular grafts market size was estimated at USD 217.75 million in 2019 and is expected to reach USD 227.03 million in 2020.
b. The global hemodialysis vascular grafts market is expected to grow at a compound annual growth rate of 4.1% from 2019 to 2025 to reach USD 276.48 billion by 2025.
b. Polytetrafluoroethylene dominated the hemodialysis vascular grafts market with a share of 44.3% in 2019.
b. Some key players operating in the hemodialysis vascular grafts market include W.L. Gore & Associates; C. R. Bard, Inc.; Terumo Medical Corporation; LeMaitre Vascular, Inc.; and Getinge AB.
b. Key factors that are driving the hemodialysis vascular grafts market growth include the increasing prevalence of renal disorders, growing adoption of biological access grafts, and technological advancements in hemodialysis vascular grafts.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.